Artivion (NYSE:AORT - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Artivion to post earnings of $0.03 per share for the quarter. Artivion has set its FY 2024 guidance at EPS.Persons that are interested in participating in the company's earnings conference call can do so using this link.
Artivion (NYSE:AORT - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.04. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. The business had revenue of $98.02 million during the quarter, compared to the consensus estimate of $97.70 million. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Artivion Price Performance
Artivion stock traded down $0.30 during trading on Thursday, reaching $26.33. The company had a trading volume of 148,752 shares, compared to its average volume of 221,856. The firm has a market capitalization of $1.10 billion, a PE ratio of -124.76 and a beta of 1.74. The firm's 50-day simple moving average is $25.99 and its 200 day simple moving average is $24.78. The company has a debt-to-equity ratio of 1.07, a quick ratio of 4.04 and a current ratio of 5.63. Artivion has a 1-year low of $12.47 and a 1-year high of $29.24.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on AORT. Stifel Nicolaus boosted their target price on shares of Artivion from $28.00 to $30.00 and gave the stock a "buy" rating in a research note on Friday, September 13th. Oppenheimer boosted their price objective on Artivion from $25.00 to $30.00 and gave the stock an "outperform" rating in a research note on Friday, August 9th. JMP Securities assumed coverage on Artivion in a research report on Wednesday, October 23rd. They issued an "outperform" rating and a $33.00 target price on the stock. Finally, Needham & Company LLC reiterated a "buy" rating and set a $30.00 price target on shares of Artivion in a research report on Friday, September 27th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $30.60.
Read Our Latest Stock Analysis on Artivion
Insider Buying and Selling at Artivion
In other news, CAO Amy Horton sold 12,430 shares of Artivion stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the transaction, the chief accounting officer now owns 139,989 shares in the company, valued at $3,664,912.02. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Artivion news, CAO Amy Horton sold 12,430 shares of the firm's stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the completion of the sale, the chief accounting officer now owns 139,989 shares of the company's stock, valued at $3,664,912.02. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jean F. Holloway sold 3,167 shares of the company's stock in a transaction on Monday, August 26th. The shares were sold at an average price of $26.55, for a total value of $84,083.85. Following the completion of the transaction, the senior vice president now directly owns 161,932 shares in the company, valued at approximately $4,299,294.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,109 shares of company stock worth $951,935. Insiders own 8.10% of the company's stock.
About Artivion
(
Get Free Report)
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Read More
Before you consider Artivion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.
While Artivion currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
